Conclusions: This study revealed NTRK fuisons in approximately 0.3% of Chinese solid tumor pts for the first time. The NTRK gene fusions more commonly occurred in NSCLC (0.3%) and CRC (1.4%), but may occur with other targetable alterations such as EGFR-activating mutations. NGS panel sequencing showed the advantage of detecting NTRK fusion and providing structure information of partners which could potentially guide more precise treatment options. Legal entity responsible for the study: OrigiMed. (Motzer et al. Lancet Oncol 2015) We present biomarker analyses from this study. Methods: Serum samples collected at baseline were analyzed by Luminex-based xMAPV R assays for 40 candidate biomarkers. Baseline biomarker levels were correlated with PFS using Cox regression analysis. Biomarkers with the strongest associations (top 5 ranked by log-rank P-value and HR) with PFS in the LENþEVE arm were integrated into composite biomarker scores (CBS) (Voss et al. Br J Cancer 2016) All P-values are nominal. Results: Serum samples from 145 pts (LENþEVE, n ¼ 49; LEN, n ¼ 50; EVE, n ¼ 46) were analyzed. HGF, MIG, IL-18BP, IL-18, and ANG-2 concentrations demonstrated the strongest correlation with PFS and were selected for the CBS analysis. Associations with PFS are summarized in the table. In the LENþEVE arm, median PFS for pts with high (3-5) vs low (0-2) CBS was 20.1 vs 5.6 months, respectively (HR 0.28; P ¼ 0.002), whereas no significant difference between high vs low CBS was seen in the EVE arm (3.6 vs 5.5 months; HR 1.02; P ¼ 0.951). Median PFS differed significantly between treatment arms for pts with high CBS (LENþEVE vs EVE, 20.1 vs 3.6 months; P < 0.001), but not for pts with low CBS (LEN EVE vs EVE, 5.6 vs 5.5 months; P ¼ 0.329). Conclusions: In pts treated with LENþEVE, high CBS was correlated with PFS benefit; further research is needed to determine if the score can be used to identify pts who may benefit from combination therapy. Altogether, these biomarkers may be predictors of response to LENþEVE therapy in pts with mRCC. Clinical trial identification: NCT01136733. Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan Background: While established deep learning approaches for histopathology usually consist of a two-step process, a cell or region segmentation and subsequent feature calculation, end-to-end learning has been used to predict patient survival directly from digital tissue sections. We aimed to apply a deep learning approach in a series of gastric cancer (GC) tissue microarrays (TMAs) in order to identify regions in the tissue related to a high-risk of poor survival, and subsequently stratify patients into two risk groups. Methods: Image patches (size 80mm) were extracted from 469 TMA cores constructed from 248 GC resection specimens which were scanned after immunohistochemistry for CD8 and KI67. For each stain, a survival convolutional neural network (CNN) was trained to maximize a log partial likelihood derived from the Cox proportional hazards model [Mobadersany, PNAS, 2018] and to predict patch-based risks for cancer-specific death in a 10-fold pre-validation procedure, creating risk heatmaps for each core. Aggregation from patch to patient level was done by averaging the risks from all patches of each patient. Results: We generated risk heatmaps comprising on median 1300 image patches per patient for the CD8 and KI67 stained tissue sections. Stratifying patients into low-and high-risk groups by taking the cohort median as threshold led to a significant log-rank test p-value (<0.01). Regarding the Lauren classification, the diffuse type was associated with higher risks than the intestinal type (T-test p-value < 0.015). Visual assessment of the risk heatmaps revealed an association of low-risk regions in CD8-stained sections with clusters of CD8(þ) cells and presence of CD8(þ) cells in stroma, whereas tumor epithelium and stroma regions with a low density of CD8(þ) cells are associated with higher risks. Conclusions: We applied survival CNNs to IHC stained gastric cancer tissue samples to directly associate image regions with cancer-specific death risks. This information may be used to deepen our knowledge on how tissue morphology relates to survival risk, and to stratify patients into high and low risk groups. Our results will be extended to other biomarkers and will be validated using data from another clinical site. Legal entity responsible for the study: Heike I. Grabsch. Pathology Group, Foundation Medicine Inc., Cambridge, MA, USA Background: Kinase fusions (KF), such as those involving ALK, are eminently targetable genomic alterations (GA) in lung and other cancers, the latter suggested by early clinical evidence (PMID: 29079636). We undertook a review of 7260 patient samples from a tertiary cancer care-focused network of five hospitals assayed with comprehensive genomic profiling (CGP). Methods: Hybrid capture based CGP was performed on 7260 advanced cancer cases (12/2012-2/2018), with assessment of at least 186 genes (intronic baiting for at least 14) in tissue, and 62 genes (intronic baiting for 6) in circulating tumor DNA samples. Tumor mutational burden (TMB) was determined up to 1.2 Mbp of sequenced DNA. Results: 77/7260 (1%) samples in this series harbored KF. Patients (pts) with KFþ tumors had a median age of 53 years vs. 56 years in the overall population. The TMB in KFþ cases was 3.51 mut/Mb vs. 4.39 mut/Mb for all cases. KF were found in 55 lung (71%) and 22 (29%) non-lung samples. Of KFþ cases, 71% were non-small cell lung cancer, and the remainder were sarcoma (5%), breast cancer (4%), thyroid (4%), cancer of unknown primary (4%), pancreatic (3%), colorectal (3%) and others (1% each).
Background: In a randomized, 3-arm, phase 2 trial of patients (pts) with metastatic renal cell carcinoma (mRCC) following 1 VEGF-targeted therapy, LENþEVE improved median progression-free survival (PFS) compared with EVE (hazard ratio [HR] 0.40; 95% confidence interval [CI] 0.24-0.68; P < 0.001) or LEN (HR 0.66; 95% CI 0.39-1.10; P ¼ 0.121). (Motzer et al. Lancet Oncol 2015) We present biomarker analyses from this study. Methods: Serum samples collected at baseline were analyzed by Luminex-based xMAPV R assays for 40 candidate biomarkers. Baseline biomarker levels were correlated with PFS using Cox regression analysis. Biomarkers with the strongest associations (top 5 ranked by log-rank P-value and HR) with PFS in the LENþEVE arm were integrated into composite biomarker scores (CBS) (Voss et al. Br J Cancer 2016) All P-values are nominal. Results: Serum samples from 145 pts (LENþEVE, n ¼ 49; LEN, n ¼ 50; EVE, n ¼ 46) were analyzed. HGF, MIG, IL-18BP, IL-18, and ANG-2 concentrations demonstrated the strongest correlation with PFS and were selected for the CBS analysis. Associations with PFS are summarized in the table. In the LENþEVE arm, median PFS for pts with high (3-5) vs low (0-2) CBS was 20.1 vs 5.6 months, respectively (HR 0.28; P ¼ 0.002), whereas no significant difference between high vs low CBS was seen in the EVE arm (3.6 vs 5.5 months; HR 1.02; P ¼ 0.951). Median PFS differed significantly between treatment arms for pts with high CBS (LENþEVE vs EVE, 20.1 vs 3.6 months; P < 0.001), but not for pts with low CBS (LEN EVE vs EVE, 5.6 vs 5.5 months; P ¼ 0.329). Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan Background: While established deep learning approaches for histopathology usually consist of a two-step process, a cell or region segmentation and subsequent feature calculation, end-to-end learning has been used to predict patient survival directly from digital tissue sections. We aimed to apply a deep learning approach in a series of gastric cancer (GC) tissue microarrays (TMAs) in order to identify regions in the tissue related to a high-risk of poor survival, and subsequently stratify patients into two risk groups. Methods: Image patches (size 80mm) were extracted from 469 TMA cores constructed from 248 GC resection specimens which were scanned after immunohistochemistry for CD8 and KI67. For each stain, a survival convolutional neural network (CNN) was trained to maximize a log partial likelihood derived from the Cox proportional hazards model [Mobadersany, PNAS, 2018] and to predict patch-based risks for cancer-specific death in a 10-fold pre-validation procedure, creating risk heatmaps for each core. Aggregation from patch to patient level was done by averaging the risks from all patches of each patient. Results: We generated risk heatmaps comprising on median 1300 image patches per patient for the CD8 and KI67 stained tissue sections. Stratifying patients into low-and high-risk groups by taking the cohort median as threshold led to a significant log-rank test p-value (<0.01). Regarding the Lauren classification, the diffuse type was associated with higher risks than the intestinal type (T-test p-value < 0.015). Visual assessment of the risk heatmaps revealed an association of low-risk regions in CD8-stained sections with clusters of CD8(þ) cells and presence of CD8(þ) cells in stroma, whereas tumor epithelium and stroma regions with a low density of CD8(þ) cells are associated with higher risks. Conclusions: We applied survival CNNs to IHC stained gastric cancer tissue samples to directly associate image regions with cancer-specific death risks. This information may be used to deepen our knowledge on how tissue morphology relates to survival risk, and to stratify patients into high and low risk groups. Our results will be extended to other biomarkers and will be validated using data from another clinical site. Legal entity responsible for the study: Heike I. Grabsch. Pathology Group, Foundation Medicine Inc., Cambridge, MA, USA Background: Kinase fusions (KF), such as those involving ALK, are eminently targetable genomic alterations (GA) in lung and other cancers, the latter suggested by early clinical evidence (PMID: 29079636). We undertook a review of 7260 patient samples from a tertiary cancer care-focused network of five hospitals assayed with comprehensive genomic profiling (CGP). Methods: Hybrid capture based CGP was performed on 7260 advanced cancer cases (12/2012-2/2018), with assessment of at least 186 genes (intronic baiting for at least 14) in tissue, and 62 genes (intronic baiting for 6) in circulating tumor DNA samples. Tumor mutational burden (TMB) was determined up to 1.2 Mbp of sequenced DNA. Results: 77/7260 (1%) samples in this series harbored KF. Patients (pts) with KFþ tumors had a median age of 53 years vs. 56 years in the overall population. The TMB in KFþ cases was 3.51 mut/Mb vs. 4.39 mut/Mb for all cases. KF were found in 55 lung (71%) and 22 (29%) non-lung samples. Of KFþ cases, 71% were non-small cell lung cancer, and the remainder were sarcoma (5%), breast cancer (4%), thyroid (4%), cancer of unknown primary (4%), pancreatic (3%), colorectal (3%) and others (1% each).
LENþEVE
Of KFþ non-lung cases, 39% had BRAF fusions, 30% had ALK fusions, 26% had RET fusions, and 4% had ROS1 fusions. One KFþ sarcoma pt received matched targeted therapy with ALK inhibitors including ceritinib and crizotinib. More recently, in 2017 samples alone, 42% (10/24) of KFþ cases were non-lung. Conclusions: Greater access to CGP has led to increased detection of advanced cancer patients with tumors harboring KF, particularly those with non-lung cancers. The low frequency of the latter is a challenge for clinical investigation. As such, innovative solutions such as basket trial for kinase inhibitors are needed, which may be feasible in an integrated cancer care system with high patient volume. Legal entity responsible for the study: Ankur Parikh. Background: Due to the compelling predictive value of companion diagnostic (CDx) biomarkers tied to targeted and immune-based therapies, well-characterized robust analytic and clinical validation of genomic assays has become mandatory. An NGSbased CGP (comprehensive genomic profiling) platform was developed in compliance with FDA guidelines for CDx indications. Methods: DNA extracted from FFPE tumor tissue underwent whole-genome shotgun library construction and hybridization-based capture, followed by sequencing using Illumina HiSeq 4000. Sequence data were processed using a proprietary analysis pipeline designed to identify sub substitutions, indels, copy number alterations, genomic rearrangements, microsatellite instability (MSI), and tumor mutational burden (TMB) in 324 genes.
Results: Clinical validity was demonstrated by establishing statistical non-inferiority between CGP and the respective approved CDx, e.g. cobas EGFR and BRAF mutational testing, ALK rearrangements with FISH and IHC, ERBB2 amplification with FISH, and others. For analytical validity, concordance with an orthogonal NGS platform was 94.6% for substitutions and indels, and within-assay reproducibility had positive percent agreement (PPA) of 99.4%. TMB was analytically validated via concordance with whole-exome sequencing. For the first 616 patients (25% non-small cell lung cancer) assayed in clinical care, 6.8% of cases had TMB exceeding 20 mut/Mb, with 25% of these also harboring microsatellite instability. For 143 NSCLC cases, >50% harbored 10 mut/Mb. Of 354 cases with CDx findings possible, 25.6% had such findings, which were split nearly evenly between indications to benefit from and contraindications to targeted therapies.
